Clinical Trial

Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the absolute bioavailability of SC administered cizutamig in healthy adult participants.
Protocol Amendment History 7 changes
critical Trial completed 2026-07-23
notable Primary completion moved earlier: 2026-06 -> 2026-04-16 2026-07-23
minor Completion pushed: 2026-06 -> 2026-07-14 2026-07-23
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-06
notable Enrollment increased: 20 -> 24 participants 2026-05-06
notable Primary completion pushed: 2026-03 -> 2026-06 2026-05-06
minor Completion pushed: 2026-03 -> 2026-06 2026-05-06
Trial Details
NCT Number NCT07236411
Lead Sponsor Candid Therapeutics
Conditions Healthy Participants Study
Enrollment 24 participants
Start Date 2025-12-04
Primary Completion 2026-04-16 (estimated)
Study Completion 2026-07-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-22